OKYO Pharma (OKYO) News Today $1.07 0.00 (0.00%) Closing price 04/11/2025 03:57 PM EasternExtended Trading$1.08 +0.01 (+1.40%) As of 04/11/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period OKYO Pharma (NASDAQ:OKYO) & Kyverna Therapeutics (NASDAQ:KYTX) Financial ContrastApril 10 at 1:52 AM | americanbankingnews.comOKYO Pharma CEO discusses FDA Fast Track filing for urcosimod - ICYMIApril 5, 2025 | proactiveinvestors.comOKYO Pharma confirms stability of drug candidateApril 2, 2025 | uk.investing.comOKYO Pharma reports long-term shelf stability of corneal pain treatmentMarch 31, 2025 | proactiveinvestors.comOKYO Pharma Announces Positive Data in Long-Term Stability of UrcosimodMarch 31, 2025 | globenewswire.comOKYO Pharma Limited (NASDAQ:OKYO) Short Interest UpdateOKYO Pharma Limited (NASDAQ:OKYO - Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 338,000 shares, a growth of 30.4% from the February 13th total of 259,200 shares. Currently, 1.4% of the shares of the stock are sold short. Based on an average trading volume of 150,800 shares, the days-to-cover ratio is presently 2.2 days.March 18, 2025 | marketbeat.comOKYO Pharma Files Application for Fast Track Designation for Urcosimod in Treatment of Neuropathic Corneal PainMarch 12, 2025 | nasdaq.comOKYO Pharma seeks FDA Fast Track for eye pain drugMarch 12, 2025 | uk.investing.comOKYO Pharma seeks FDA fast track for eye pain treatmentMarch 12, 2025 | uk.investing.comOKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatmentMarch 10, 2025 | proactiveinvestors.comOkyo Pharma files for FTD with FDA for urcosimodMarch 10, 2025 | markets.businessinsider.comOKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal PainMarch 10, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)February 18, 2025 | markets.businessinsider.comBuy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market PotentialFebruary 14, 2025 | tipranks.comOKYO Pharma secures USAN designation ‘urcosimod' for lead assetFebruary 12, 2025 | proactiveinvestors.comOKYO Pharma’s Lead Asset OK-101 Receives USAN as UrcosimodFebruary 12, 2025 | tipranks.comYi Chen’s Buy Recommendation on OKYO Pharma: Promising Potential of OK-101 for Neuropathic Corneal Pain Amid Financial and Regulatory ChallengesFebruary 10, 2025 | tipranks.comOKYO Pharma poised for multi-billion-dollar opportunity in ocular treatment market, analysts believeJanuary 31, 2025 | proactiveinvestors.comOKYO Pharma insiders acquire sharesJanuary 31, 2025 | proactiveinvestors.comOKYO Pharma Executives Increase Shareholdings, Affirming Market ConfidenceJanuary 31, 2025 | tipranks.comOKYO Pharma Announces Chairman and CEO Acquire SharesJanuary 31, 2025 | globenewswire.comOKYO Pharma nears full enrollment for neuropathic corneal pain trial with results expected by year-endJanuary 29, 2025 | proactiveinvestors.comOKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second QuarterJanuary 29, 2025 | markets.businessinsider.comOkyo Pharma receives $1.4M in non-dilutive financingJanuary 23, 2025 | markets.businessinsider.comOKYO Pharma secures $1.4 million in non-dilutive fundingJanuary 22, 2025 | msn.comOKYO Pharma Receives $1.4 Million in Non-Dilutive FundingJanuary 22, 2025 | markets.businessinsider.comOKYO Pharma secures $1.4 million non-dilutive fundingJanuary 22, 2025 | msn.comOKYO Pharma secures non-dilutive funding to advance clinical programsJanuary 22, 2025 | proactiveinvestors.comOKYO Pharma Secures $1.4 Million to Boost Ophthalmic InnovationsJanuary 22, 2025 | tipranks.comMitsubishi Chemical picks Bain as preferred bidder for pharma unit, sources sayJanuary 21, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS) and Veru (VERU)January 2, 2025 | markets.businessinsider.comOKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceNovember 26, 2024 | markets.businessinsider.comOKYO Pharma to Highlight Innovations at BTIG ConferenceNovember 26, 2024 | tipranks.comJapan pharma mulls suing lawmaker who likened new COVID vaccine to 'biological weapon'November 2, 2024 | msn.comJapan's Takeda raises full-year profit forecast amid restructuringOctober 31, 2024 | msn.comOKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conferenceOctober 30, 2024 | proactiveinvestors.comOKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMIOctober 26, 2024 | proactiveinvestors.comOKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trialOctober 23, 2024 | proactiveinvestors.comOKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainOctober 23, 2024 | globenewswire.comOKYO Pharma Begins Key Phase 2 Trial for Eye Pain DrugOctober 18, 2024 | finance.yahoo.comOKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatmentOctober 16, 2024 | proactiveinvestors.comLife-saving cancer drug a boon for patients, but its price prompts debateSeptember 27, 2024 | msn.comBuy Rating on OKYO Pharma: U.S. Patent and Strong Trial Results for OK-101 Boosts Market PotentialAugust 27, 2024 | markets.businessinsider.comOKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseAugust 27, 2024 | markets.businessinsider.comOKYO Pharma secures key US patent for dry eye disease therapyAugust 27, 2024 | proactiveinvestors.comOKYO Pharma Exec Chairman Increases StakeAugust 25, 2024 | uk.investing.comOKYO Pharma CEO Interview to Air on Bloomberg TVAugust 23, 2024 | globenewswire.comOKYO Pharma Announces Chairman Acquires SharesAugust 23, 2024 | globenewswire.comOKYO Pharma chairman acquires more shares in the companyAugust 21, 2024 | proactiveinvestors.comOKYO Pharma Announces Chairman Acquires SharesAugust 21, 2024 | globenewswire.com Remove Ads Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address OKYO Media Mentions By Week OKYO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OKYO News Sentiment▼0.960.95▲Average Medical News Sentiment OKYO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OKYO Articles This Week▼31▲OKYO Articles Average Week Remove Ads Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PBYI News CTNM News RAPT News TNGX News TARA News KRRO News ACTU News LYEL News GLSI News IKT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OKYO) was last updated on 4/12/2025 by MarketBeat.com Staff From Our PartnersControversial opinion: Volume isn't enough.Don’t be fooled by volume alone — it's just one piece of the trading puzzle. High demand doesn’t matter if sup...MillPub | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe rotation into gold miners is on.They’re deeply undervalued gold developers with massive in-the-ground, proven resources - and now, fast-track ...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredPlease — Don’t PanicMarkets are in turmoil — but TradeSmith CEO Keith Kaplan says panic isn’t the answer. Instead, he believes thi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OKYO Stock Free OKYO Stock Alerts